Adicet bio announces fda clearance of ind application for adi-270 in renal cell carcinoma

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for autoimmune diseases and cancer, today announced that the u.s. food and drug administration (fda) has cleared the company's investigational new drug (ind) application to evaluate adi-270, an armored allogeneic “off-the-shelf” gamma delta chimeric antigen receptor (car) t cell therapy candidate targeting cd70.
ACET Ratings Summary
ACET Quant Ranking